Vertex/Tibotec's telaprevir shines in hard-to-treat HCV patients
This article was originally published in Scrip
Executive Summary
Vertex/Tibotec's protease inhibitor telaprevir met expectations in its third, and final, Phase III trial, demonstrating efficacy in treatment-experienced hepatitis C virus (HCV) genotype 1 patients. The top-line results from the REALIZE trial support positive data from two earlier pivotal trials in treatment-naïve patients.